OncoMatch/Clinical Trials/NCT07014319
Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
Is NCT07014319 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Maribavir for cytomegalovirus (cmv).
Treatment: Maribavir — This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: bispecific antibody (Teclistamab, Elranatamab, Talquetamab, Cevostamab, ABBV383, Mosunetuzumab, Glofitamab, Epcoritamab, Odronextamab)
receiving one of the following bispecific antibodies: Multiple Myeloma: Teclistamab, Elranatamab, Talquetamab, Cevostamab, ABBV383 Lymphomas: Mosunetuzumab, Glofitamab, Epcoritamab, Odronextamab
Lab requirements
Kidney function
Creatinine clearance <10 mL/min or requiring dialysis (Cockcroft-Gault formula used)
Liver function
AST or ALT >5 × ULN, total bilirubin >3 × ULN (except Gilbert's syndrome) excluded
Creatinine clearance <10 mL/min or requiring dialysis...AST or ALT >5 × ULN...Total bilirubin >3 × ULN (except Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07014319 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received bispecific antibody.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify